All In Biotech

Drug Trial Radar · NCT00048152

A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients

A Randomized, Open-label Study Comparing the Effects of Low-dose Cyclosporine vs Cyclosporine Withdrawal on Renal Function in Kidney Transplant Patients Treated With CellCept and Daclizumab

Last checked: Nov 20, 2026Latest source record: Nov 2, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 539 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

539

Actual

Start

Dec 2000

Primary completion

Mar 2006

Study completion Mar 2006

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Oct 25, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will compare kidney function in kidney transplant patients following treatment with various combinations of Zenapax, CellCept, corticosteroids, and Neoral (Cyclosporine). The anticipated time on study treatment is 6-12 months, and the target sample size is 500+ individuals.

Conditions

  • Kidney Transplantation

Interventions

  • CorticosteroidsDrug

    As prescribed

  • NeoralDrug

    Low dose (target trough level 50-100ng/mL)

  • NeoralDrug

    Standard dose (target trough level 150-300ng/mL)

  • ZenapaxDrug

    2mg/kg iv first dose, then 1mg/kg every 2 weeks

  • mycophenolate mofetil [CellCept]Drug

    1g po bid

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Renal function (as measured by GFR)Time frame: 12 months post-transplant

Locations

36 sites in 12 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    San Francisco, California

  • Site not named

    Gainesville, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Livingston, New Jersey

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Charleston, South Carolina

  • Site not named

    Falls Church, Virginia

  • Site not named

    Adelaide, Australia

  • Site not named

    Sydney, Australia

  • Site not named

    Brussels, Belgium

  • Site not named

    Leuven, Belgium

  • Site not named

    Calgary, Alberta, Canada

  • Site not named

    Edmonton, Alberta, Canada

  • Site not named

    Vancouver, British Columbia, Canada

  • Site not named

    Saskatoon, Saskatchewan, Canada

  • Site not named

    Vandœuvre-lès-Nancy, France

  • Site not named

    Berlin, Germany

  • Site not named

    Hanover, Germany

  • Site not named

    Münster, Germany

  • Site not named

    Mexico City, Mexico

  • Site not named

    Monterrey, Mexico

  • Site not named

    Oslo, Norway

  • Site not named

    Warsaw, Poland

  • Site not named

    Wroclaw, Poland

  • Site not named

    Barcelona, Spain

  • Site not named

    Barcelona, Spain

  • Site not named

    Córdoba, Spain

  • Site not named

    Málaga, Spain

  • Site not named

    Santander, Spain

  • Site not named

    Valencia, Spain

  • Site not named

    Gothenburg, Sweden

  • Site not named

    Malmö, Sweden

  • Site not named

    Birmingham, United Kingdom

  • Site not named

    Glasgow, United Kingdom

  • Site not named

    Leicester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.